FCF Life Sciences Venture Capital Monitor – Europe 04/2022 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 04/2022”. The Monitor is a monthly published overview of venture capital trends in the European Life Sciences sector.

As of the end of  April 2022 we identify the following current VC trends in Europe:

  • In 2022, overall Life Sciences funding has reached EUR 3,421m so far
  • Top 5 Deals exceed EUR 70m each, largest transaction amounted to EUR 500m in Doctolib (France)
  • Two of the Top 5 Deals took place in Germany, Patient21 (EUR 125m) and Ada Health (EUR 106m)
  • Bpifrance dominates the Top 5 Investors (by deal volume), followed by Eurazeo (France) and General Atlantic (United States)
  • The Biotech sector received 43% of the total investment volume
  • Oncology dominates as the top indication of the Biotechnology sector

To access the full report, please click here.

By Dr. Mathias Schott, Sebastian Sommer and Johannes Link

Share
[a-zA-Z0-9_.-]
[a-zA-Z0-9_.-]
[a-zA-Z0-9]
[a-zA-Z0-9]